Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joint-Wit Medical & Pharmaceutical Industry And SU BioMedicine To Set Up Joint Venture

This article was originally published in PharmAsia News

Executive Summary

Sichuan Joint-Wit Medical & Pharmaceutical Industry and Netherlands-based SU BioMedicine will each invest RMB 5 million to set up a 50:50 joint venture, which will operate businesses such as herbal medicine, TCM, food additive R&D, marketing, as well as Chinese medicine intermediates production. SU BioMedicine, a subsidiary of the Netherlands Organization for Applied Scientific Research, currently collaborates with many Chinese research institutions and enterprises to develop plant medicine for metabolism syndrome. The tie-up will improve Joint-Wit's international competitiveness through the introduction of advanced pharmaceutical techniques. The joint company will establish a GMP-compliant production line within existing Joint-Wit facilities to produce plant medicine and food addictives, to be developed into plant or natural medicine for the EU and U.S. markets. (Click here for more - Chinese Language)

You may also be interested in...



QUOTED. 9 April 2020. Frans van Houten.

Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

UsernamePublicRestriction

Register

SC069784

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel